Imogene Dunn

Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator

Adrian Vella, Jennifer L. R. Freeman, Imogene Dunn et al. · Science Translational Medicine · 2019 · 73 citations

The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes

Klara R. Klein, Jennifer L. R. Freeman, Imogene Dunn et al. · Diabetes Care · 2021 · 39 citations · Full text

Risk-Based Monitoring: A Closer Statistical Look at Source Document Verification, Queries, Study Size Effects, and Data Quality

Vadim Tantsyura, Imogene Dunn, Kaye Fendt et al. · Therapeutic Innovation & Regulatory Science · 2015 · 34 citations

Reliability, Engineering, Data Science +13

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial

D. Clark Files, Neil R. Aggarwal, Timothy E. Albertson et al. · EClinicalMedicine · 2023 · 33 citations · Full text

Extended Risk-Based Monitoring Model, On-Demand Query-Driven Source Data Verification, and Their Economic Impact on Clinical Trial Operations

Vadim Tantsyura, Imogene Dunn, Joel Waters et al. · Therapeutic Innovation & Regulatory Science · 2015 · 19 citations

Engineering, Data Science, Health Policy +14